- 11May, 2026
Miami, FL – May 12, 2026 — TAXIS Pharmaceuticals, a clinical-stage company developing investigational anti-resistance therapies to address antimicrobial resistance (AMR), today announced the publication of preclinical data in the peer-reviewed journal Antibiotics describing TXA11114, an investigational indole carboxamide efflux pump inhibitor (EPI) designed to [...]
Antibiotic-Resistant STIs: Men’s Health Is Entering A New Era Of Therapeutic Risk
This article was originally published on drugdiscoveryonline.com. By Gregory G. Mario, MBA, president and CEO, TAXIS Pharmaceuticals For decades, sexually transmitted infections (STIs), such as gonorrhea and chlamydia, were viewed as straightforward to treat. A single injection or short oral course of antibiotics was typically sufficient. [...]
Confronting Antibiotic-Resistant STIs: Advancing Next-Generation DHFR Inhibitors for Dual-Pathogen Coverage
For decades, infections like gonorrhea and chlamydia were treated as routine; a quick course of antibiotics and life went on. Now, that comfort is collapsing. Neisseria gonorrhoeae has steadily outmaneuvered drug after drug, such as macrolides, fluoroquinolones and more;1 and today we rely on a [...]
Antibiotic-Resistant Gonorrhea Emerges as a Growing Men’s Health Crisis During STI Awareness Month
Author(s) Contagion Editorial Team TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on the disease burden, and an overview of his company’s pipeline around developing a therapy for this STI. April is sexually transmitted infection (STI) Awareness Month, and with it brings [...]
- 24Mar, 2026
World Health Day is a good moment to call attention to a silent emergency that’s putting the health of everyone on our planet at risk: Antimicrobial resistance (AMR) is quietly eroding the foundations of modern medicine. On a day when we talk about equity and [...]
- 12Feb, 2026
February 10, 2026 — TAXIS Pharmaceuticals Australia Pty Ltd has named Angela Fonceca, PhD, an industry professional with extensive biopharma experience, to its Board of Directors. TAXIS Pharmaceuticals, a clinical-stage company focused on developing investigational therapies to combat multidrug-resistant bacterial infections and address antimicrobial resistance [...]
- 2Feb, 2026
After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point. While US government prioritisation of AMR will likely remain low in 2026, the EU and Australia are ramping up incentives and R&D funding. [...]
